Accellix
Accelix is a biotechnology company that helps cell and gene therapy companies to meet their key product QC requirements. It provides an instrument and a room temperature stable cartridge to gather multi-parameter results.
Accellix has raised €8.1M across 1 funding round from 1 investor, most recently a Series D+ round in Oct 2020. Based in Jerusalem, Israel; founded 2007; active in Healthtech. Data as of 28 Oct 2026.
Jerusalem, IsraelFounded 2007
Total raised
€8.1M
€8,072,740
Funding rounds
1
Investors
1
distinct backers
Active since
2020-10
latest 2020-10
Funding by year
EUR raised per yearAccellix — funding by year — interactive chart.
Data table
| Accellix — funding by year | |
|---|---|
| 2020 | €8.1M |
Signals
High confidenceRaise-next likelihood10
base rate 53% for Series D+
- ▼ Dormant (no round in 3+ cohort gaps)
- ▼ Low backer re-investment
Timing: dormant vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
1 round| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2020-10-06 | Series D+ | €8.1M | bioMerieux | View deal → |
Investors
1Related news
Similar companies
same sector or country- Philips€2.6BNetherlands · Healthtech
- Isomorphic Labs€2.3BUK · Healthtech
- CMR Surgical€1.5BUK · Healthtech
- Roivant Sciences€1.1BSwitzerland · Healthtech
- Neko Health€924MSweden · Healthtech
- Trax€789MIsrael · Software
Global coverage: FundingData